3164 Stock Overview
Engages in the research, development, manufacture, and sale of functional probiotic supplements in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
GenMont Biotech Incorporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$20.00 |
| 52 Week High | NT$25.35 |
| 52 Week Low | NT$20.00 |
| Beta | 0.34 |
| 11 Month Change | -10.31% |
| 3 Month Change | -11.89% |
| 1 Year Change | -16.49% |
| 33 Year Change | -16.67% |
| 5 Year Change | -20.16% |
| Change since IPO | -32.81% |
Recent News & Updates
Recent updates
We Think That There Are More Issues For GenMont Biotech Incorporation (TWSE:3164) Than Just Sluggish Earnings
Mar 19
Should You Or Shouldn't You: A Dividend Analysis on GenMont Biotech Incorporation (TPE:3164)
Apr 04GenMont Biotech Incorporation's(TPE:3164) Share Price Is Down 26% Over The Past Five Years.
Feb 14
Is GenMont Biotech Incorporation's (TPE:3164) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 24Tread With Caution Around GenMont Biotech Incorporation's (TPE:3164) 3.5% Dividend Yield
Jan 03Are GenMont Biotech Incorporation's (TPE:3164) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 08Shareholder Returns
| 3164 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -5.0% | -3.8% | -3.4% |
| 1Y | -16.5% | 2.1% | 30.2% |
Return vs Industry: 3164 underperformed the TW Biotechs industry which returned 2.1% over the past year.
Return vs Market: 3164 underperformed the TW Market which returned 30.2% over the past year.
Price Volatility
| 3164 volatility | |
|---|---|
| 3164 Average Weekly Movement | 2.2% |
| Biotechs Industry Average Movement | 4.3% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 3164 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 3164's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | n/a | www.genmont.com.tw |
GenMont Biotech Incorporation engages in the research, development, manufacture, and sale of functional probiotic supplements in Taiwan. The company offers functional probiotics raw materials, capsules, powder, tablets, and liquid products; and original formula design and manufacturing, and equipment manufacturing services on health care food, as well as cooperates in the research, production, and clinical trial of various products. GenMont Biotech Incorporation was founded in 2000 and is headquartered in Tainan City, Taiwan.
GenMont Biotech Incorporation Fundamentals Summary
| 3164 fundamental statistics | |
|---|---|
| Market cap | NT$1.73b |
| Earnings (TTM) | NT$53.14m |
| Revenue (TTM) | NT$368.52m |
32.6x
P/E Ratio4.7x
P/S RatioIs 3164 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3164 income statement (TTM) | |
|---|---|
| Revenue | NT$368.52m |
| Cost of Revenue | NT$124.63m |
| Gross Profit | NT$243.89m |
| Other Expenses | NT$190.75m |
| Earnings | NT$53.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.61 |
| Gross Margin | 66.18% |
| Net Profit Margin | 14.42% |
| Debt/Equity Ratio | 5.4% |
How did 3164 perform over the long term?
See historical performance and comparison